To evaluate the current status of the management of hypertensive patients in Japan, we investigated 907 treated hypertensive patients (486 females and 421 males; mean age, 66.7 years) followed by cardiologists. 
Introduction
Many interventional studies suggest the importance of blood pressure (BP) management to prevent cardiovascular and cerebrovascular diseases (1) (2) (3) (4) . Angiotensin converting enzyme inhibitors (ACE-inhibitors) and calcium channel blockers (CCBs) are often recommended because they have been shown to protect hypertensive patients from organ damage. However, most of the large-scale interventional studies have utilized diuretics and/or β-blockers (1) (2) (3) 5) . Nevertheless, in Japan, physicians prefer to prescribe CCBs rather than diuretics or β-blockers, because cerebrovascular diseases are the most common cause of mortality. Additionare in line with the WHO/ISH and the JNC-VI guidelines (8, 9) . The aim of the present study was to investigate the current status of the management of hypertensive patients by cardiologists in Japan.
Methods

Study Design
This cross-sectional survey was carried out for 6 months, starting in September 2000 and lasting until March 2001, just after the JSH-2000 guidelines were announced in June 2000. A total of 34 cardiologists in 22 facilities participated in this survey (12 cardiologists in Tottori University Hospital, 12 cardiologists in 11 hospitals and 10 cardiologists in 10 private practices). Hypertensive patients treated for at least 6 months prior to this survey were included in the study. Patients who were treated without antihypertensive drugs were also enrolled. Patients who were diagnosed with whitecoat hypertension or who were prescribed one or more antihypertensive drugs for conditions other than hypertension were excluded. The participating cardiologists were asked to complete a survey detailing how each hypertensive patient was treated. Questions for which information or data was unavailable could be left blank. Each participant cardiologist was asked to enroll a maximum of 30 consecutive outpatients.
Details of the Survey and Definitions
Data on age, gender, BP, family history, risk factors, prescription(s) and concurrent diseases (including cardiovascular diseases, cerebrovascular diseases and renal insufficiency) was collected. BP was taken as the mean of the BP measured on the 3 most recent visits. Hypertension was defined using the JSH-2000 definition (systolic blood pressure (SBP) 140 mmHg and/or diastolic blood pressure (DBP) 90 mmHg). Patients who were already being treated with antihypertensive drugs for hypertension could be enrolled. The collected laboratory data included total cholesterol, triglyceride, high density lipoprotein cholesterol, uric acid, fasting blood sugar, glycohemoglobin, and urinalysis. Left ventricular hypertrophy was diagnosed on ultrasound examination and/or electrocardiography. Only patients who were current smokers were defined as smokers. Renal insufficiency was defined as serum creatinine 2.0 mg/dl. Positive proteinuria was defined as spot proteinuria 100 mg/dl. Diabetes mellitus (DM) was diagnosed according to the definitions of the Japan Diabetes Society (1999). Hypercholesterolemia was defined as total cholesterol 220 mg/dl or treatment with cholesterol-lowering drugs. Hyperuricemia was defined as a serum uric acid 7.0 mg/dl or treatment with uric acid-lowering drugs.
Statistical Analysis
Statistical analyses were performed with StatView software version 4.5 for Windows (Abacus Concepts Inc., Berkeley, USA). Comparisons among the groups were performed with analysis of variance (ANOVA) or χ 2 test. All values were expressed as the means SD. Values of p 0.05 were considered to indicate statistical significance.
Results
Control of Hypertension
In all, 907 hypertensive patients (486 females and 421 males) ranging in age from 30 to 94 years (mean age, 66.7 years) were enrolled in this survey. The detailed profiles of these patients are summarized in Table 1 . The JSH-2000 guidelines do not give strict guidance on the treatment of hypertensive patients with cerebrovascular diseases. Thus, the treatment may vary depending on the type of stroke and the patients' individual situations. For this reason, the following analysis excluded patients with cerebrovascular diseases, unless otherwise noted.
There were 792 hypertensive patients without cerebrovascular diseases (Table 2A) , with a mean SBP of 140.8 14.8 mmHg and a mean DBP of 80.1 10.7 mmHg. Although there were no significant differences in mean SBP among the 
Diabetes Mellitus
There were 150 DM patients, with a mean age of 64.6 11.2 years, compared to 66.2 11.0 years for non-DM patients. Target BP achievement rates were low in all age groups (Table 2B ). There were no significant differences in mean SBP or DBP between DM and non-DM patients (data not shown); however, the percentage of target BP achievement was substantially lower in DM patients (21.3%) than in non-DM patients (48.6%). Mean age, SBP and DBP of medicated-DM patients (n 77) and non-medicated DM patients (n 73) were not different, but the percentage of target BP achievement was better in medicated-DM patients (24.7% vs. 17.8%).
Renal Insufficiency and Proteinuria
Mean age, SBP and DBP in patients with renal insufficiency and proteinuria are summarized in Table 2C . There were no significant differences in SBP and DBP between patients with normal renal function and those with renal insufficiency. Mean SBP and age were higher in patients with proteinuria than in patients without proteinuria.
Cerebrovascular Diseases
There were 115 cerebrovascular disease patients. Their mean age was 71.3 9.0 years and was higher than that (66.0 10.9 years) of non-cerebrovascular disease patients (Table  2D ). There were no significant differences in SBP among patients with different types of cerebrovascular disease. Mean DBP in patients with a cerebral infarction was lower than that in non-cerebrovascular disease patients. 
Cardiovascular Diseases
The BP management for each cardiovascular disease is listed in Table 3 . The mean age among all patients with cardiovascular diseases was higher than that among patients with noncardiovascular diseases, except for arteriosclerosis obliterans. There were no significant differences in SBP between patients with cardiovascular diseases and those with non-cardiovascular diseases, but the mean DBP was lower in patients with cardiovascular diseases. Patients whose ocular fundi were examined were classified by stage of sclerotic change (S0-S3). While DBP decreased with increasing degrees of sclerotic change, patient age did not differ with degree of sclerotic change (data not shown).
Drug Treatment of Hypertension
All Patients Excluding Those with Cerebrovascular Diseases
The prescription rates for all patients excluding those with cerebrovascular diseases for each class of antihypertensive drugs are shown in Fig. 1 . CCBs were prescribed to 73.0% of all patients, and this percentage increased with age. Of patients 80-year-old, 80% were prescribed CCBs. Oncedaily CCBs accounted for the majority of CCB prescriptions, and the twice-or-more-daily CCB prescription rate was almost a third of the once-daily CCB prescription rate. ACEinhibitors were prescribed in all age groups at almost the same percentage (30%). ARBs and β-blockers were com- monly selected in the 70-year-old groups, but not in the 80-year-old group. Alpha-1-blockers were prescribed for less than 5% of subjects in all age groups, and were the least prescribed class of drugs. Diuretics were prescribed for 19.5% of patients 80-year-old, but they were prescribed for approximately 10% of subjects in the younger age groups.
All Patients Including Those with Cerebrovascular Diseases
Prescription profiles of all the patients in this survey, including those with cerebrovascular diseases, are shown in Table  4 . Monotherapy with CCBs, ACE-inhibitors, ARBs, β-blockers or diuretics was selected in 32.6%, 8.3%, 6.2%, 3.0% and 1.3% of the patients, respectively. Overall, CCB monotherapy was the most common choice. When monotherapy and combination therapy were combined, CCBs were selected for 73.0% of the hypertensive patients, ACE-inhibitors for 31.3% and ARBs for 18.9%. Together, ACE-inhibitors and ARBs accounted for 43.7% of prescriptions, which is almost two-thirds of the percentage of CCB prescriptions.
Diabetes Mellitus
CCBs were prescribed in 78.7% of DM patients, and this percentage was comparable to that in non-DM patients (71.7%). ACE-inhibitors were more prescribed in DM than non-DM patients, but the prescription rate did not differ between medicated and non-medicated DM patients (Fig. 2) . For ARBs, the prescription rate was higher in medicated than in non-medicated DM or non-DM patients. There were no differences in the prescription rate of β-blockers among medicated DM, non-medicated DM and non-DM patients. Overall, the prescription rate of β-blockers was comparable to that of ARBs in DM patients.
Renal Insufficiency and Proteinuria
CCBs were the most prescribed drugs in patients with renal insufficiency, though the prescription rate of ARBs was comparable to that of CCBs (Fig. 3A) . ACE-inhibitors were consistently prescribed for patients with serum creatinine 
Fig. 3. Prescription rate of antihypertensive medicines according to renal insufficiency (A) and proteinuria (B). s-Cr, serum creatinine; PU, proteinuria.
3.0 mg/dl, but not for patients with serum creatinine 3.0 mg/dl. When prescription rates were analyzed by degree of proteinuria, ACE-inhibitors, ARBs and diuretics were each prescribed to one quarter of the patients with proteinuria 300 mg/dl (Fig. 3B) . Although CCBs were the most prescribed drug for patients with proteinuria 300 mg/dl, the percentage was much lower than in those patients with proteinuria 300 mg/dl.
Cardiovascular Diseases and Peripheral Arterial Diseases
The prescription rates in patients with heart failure and ischemic heart diseases are shown in Fig. 4 . ACE-inhibitors were significantly more prescribed in patients with heart failure than in non-heart failure patients, and in fact, ACE-inhibitors were prescribed at the same rate as CCBs for these patients (Fig. 4A ). There were no significant differences in prescription rates between CCBs and ARBs in patients with and without heart failure. In patients with ischemic heart diseases, CCBs were selected slightly more often than in patients with non-ischemic heart disease (Fig. 4B) . The prescription rates of ACE-inhibitors and ARBs were not influenced by the presence of ischemic heart disease.
Cerebrovascular Diseases
CCBs were the most-prescribed drugs in patients with cerebrovascular diseases. The second-most-prescribed drugs were ACE-inhibitors and the third-most-prescribed were ARBs (Fig. 1) . This prescription profile was not different between patients with and without cerebrovascular diseases.
Discussion
In Western countries, hypertension is generally managed according to the guidelines developed by WHO/ISH and JNC-VI (8, 9) , since these guidelines were based on the clinical evidence of large-scale cohort studies and interventional studies conducted in these countries. In Japan, the dietary habits and causes of mortality are quite different from those of Western counties. Thus, in the management of hypertension in Japan, stroke prevention is the most important priority. In the summer of 2000, the Japanese Hypertension Society announced unique Japanese guidelines for the management of hypertension (JSH-2000)(7) that take into account Japanese clinical evidence in hypertension management in addition to Western evidence (10) (11) (12) (13) . Among the key features of the JSH-2000 guidelines are recommendations regarding the management of elderly hypertensive patients, since BP target levels for elderly patients can be higher than for younger patients. The aim of the current paper was to investigate the current status of hypertension management among cardiologists in Japan.
BP Control
Only 41.5% of all the enrolled patients achieved the BP target set by JSH-2000. This finding suggests that hypertensive patients are not treated aggressively enough by cardiologists in Japan, a conclusion also reached by previous reports in this country (14, 15) . Although elderly patients ( 60-yearold) appeared to be better controlled than younger patients, the mean SBPs did not differ between the two groups (Table  2A) . DBP is widely known to decrease with age in the elderly because of the progression of general arteriosclerosis. Presently, cardiologists consider the target for SBP control to be 140 mmHg in all age groups and mean DBPs resulted in decreasing with age. However, in practice, cardiologists do not appear to take age into account in their daily BP management. Japanese cardiologists could take into account the WHO/ISH and JNC-VI guidelines, which suggest strict BP control for all age groups, including the elderly. When the present results are considered in light of the initial BP target ( 140/90 mmHg) of the WHO/ISH and JNC-VI, only 42.2% of the present cohort achieved this target, with no differences among the age groups.
Although no significant differences in the management of hypertension were observed between DM patients and non-DM patients, a slight improvement was observed in the medicated-DM group over the non-medicated DM group (data not shown). A similar tendency was recently reported by Katayama et al. (15) . The results of the HOT and UKPDS39 studies suggest the importance of BP reduction to prevent cardiovascular diseases in DM patients (1, 16) . The management for hypertensive DM patients suggested by JSH-2000 is the same as that recommended by WHO/ISH and JNC-VI; hopefully, this information, along with the results of the above-mentioned large-scale cohort studies, will come to be well known among cardiologists and will positively influence the patterns of prescription.
In the present survey, only a small number of patients with
Fig. 4. Prescription rate of antihypertensive medicines according to chronic heart failure (A) and ischemic heart diseases (B). CHF, chronic heart failure; IHD, ischemic heart disease. p 0.01 vs. CHF( ); p 0.05 vs. IHD ( ).
renal insufficiency and proteinuria were studied. This makes it difficult to compare the management of hypertension in these groups to that in patients without proteinuria and no renal insufficiency. However, as Table 2C shows, cardiologists do not seem to take these conditions into account when choosing antihypertensive managements. JSH-2000 suggests that target SBP levels for elderly patients and cerebrovascular disease patients may be slightly higher than for other patients. Unfortunately, cardiologists do not appear to be cognizant of this, as shown in Table 2A and D.
As measured in all patients in this survey, DBP decreased with age. The mean age of cardiovascular disease patients was higher than that in non-cardiovascular disease patients, and the differences in DBP between these two groups could be explained by age alone. In the case of patients with cardiovascular disease, it would appear that cardiologists do not take into account the cardiovascular disease status when choosing antihypertensive managements (Table 3) . Examination of the ocular fundus revealed that sclerotic changes increased as the pulse pressure increased, although sclerotic changes were not related to mean age (data not shown). This result suggests the usefulness of ocular fundus examination in detecting early atherosclerosis.
Drug Treatment of Hypertension
In Europe, β-blockers and diuretics are the most commonly selected antihypertensive drugs (17, 18) . In Japan, β-blockers and diuretics are recommended as first-line antihypertensive drugs along with CCBs. However, in this survey, CCBs were the most prescribed drugs, with diuretics and β-blockers less commonly selected for the treatment of hypertension. This tendency has also been observed in previous surveys in Japan (15, 19) . The tendency to favor CCBs may be related to the high incidence of cerebrovascular diseases in Japan as compared to Western countries. In one of the above-mentioned previous surveys, which was conducted when ARBs were not available in Japan, CCBs were prescribed to almost 80% of elderly patients (19) . When the data from the present survey were analyzed according to the age groups in the previous study, 74.0% of patients over 50-year-old were prescribed CCBs. In fact, in all stages of concurrent diseases and in all age groups, CCBs were the most prescribed drugs. The high rate of CCB prescriptions in Japan probably reflects the Japanese cardiologists' opinion that CCBs are reliable antihypertensive drugs.
Although there had been only 2 years of experience in the use of ARBs in Japan at the time of this survey, ARBs have become one of the most prescribed drugs in the younger age groups, with a prescription rate of 24.3%. Sometimes ARBs were prescribed as a substitute for an ACE-inhibitor due to dry cough, a well-known side effect of ACE-inhibitors. Because ACE-inhibitors have been shown to improve cardiovascular outcomes (16, (20) (21) (22) (23) , it is thought that ARBs possess almost the same beneficial effects as ACE-inhibitors (24, 25) . Thus, in recent years in Japan, physicians have tended to select either ACE-inhibitors or ARBs. In this survey, a total of 43.7% of the patients were prescribed ACE-inhibitors or ARBs (18.9% of the patients were prescribed ARBs). In the previous survey by Muratani et al. (19) , ACE-inhibitors were prescribed to about 30% of the patients, which is very similar to the rate found by the present survey (31.3%).
ARBs were prescribed more commonly in patients with renal insufficiency than in patients with normal renal function, at a rate similar to CCBs (Fig. 3A) . This was probably related to the fact that ARBs are thought to have a renoprotective effect similar to that of ACE-inhibitors. In addition, ARBs are metabolized by the liver and not the kidneys. ACE-inhibitors were prescribed less often than ARBs in patients with serum creatinine 3.0 mg/dl, because caution must be exercised with the use of ACE-inhibitors in patients with renal insufficiency with serum creatinine 2.0 mg/dl. In addition, ARBs were prescribed at the same rate as ACEinhibitors in patients with proteinuria ( Fig. 3B ), indicating that, among cardiologists, ARBs may have already become the drugs of choice for hypertensive patients with renal insufficiency and/or proteinuria. Because only a small number of interventional studies on the effectiveness of ARBs have been reported (26) (27) (28) , more detailed studies will be needed before ARBs can be widely accepted as a substitute for ACE-inhibitors.
Among heart failure patients, ACE-inhibitors were more often selected, as shown in Fig. 4A . Several well-known interventional studies have documented the efficacy of ACEinhibitors for treatment of heart failure patients (21, 22, 29) , and this information is widely known among cardiologists. Currently, similar trials with ARBs are ongoing; their results may influence the selection of antihypertensive medications for heart failure patients in the future (30, 31) .
In DM patients, ACE-inhibitors were commonly prescribed (Fig. 2) . Since many studies have suggested that ACE-inhibitors benefit DM patients, this may have influenced cardiologists in their choice of ACE-inhibitors for these patients (16, (32) (33) (34) . Beta-blockers were prescribed at the same rate in DM patients as in non-DM patients, and they were more often selected in heart failure patients than in non-heart failure patients. These selections were reasonable, since β-blockers have been proven effective for these diseases (16, 35, 36) . However, the prescription rate of β-blockers was extremely low in the present survey as compared to that in the previous survey by Muratani et al. (19) . On the other hand, the α-blocker and diuretic use documented in the present survey was comparable to that in the previous survey. Unfortunately, it is very difficult to directly compare these two surveys due to differences in locales and populations. Further studies in various locations with differing populations will be needed to better assess the trends in prescription patterns.
This survey was performed just after the JSH-2000 guidelines were announced. The cardiologists surveyed did take into account currently available information, especially on cardiovascular diseases, when deciding on treatment. However, most of the time, their management of hypertension was not satisfactory. This survey was performed among cardiologists, experts in the field of cardiovascular diseases. Thus, it would be expected that better BP control would be achieved among this group than among non-specialist physicians. Obviously, to protect hypertensive patients from the complications of hypertension, more detailed management plans tailored to individual patient needs are required. In this way, better BP control could be achieved, with a decrease in morbidity and mortality. In fact, in the near future we will need to investigate how the JSH-2000 guidelines have affected the mortality and morbidity of hypertensive patients in Japan.
